Management discusses the KOMET-007 combination trial of the Company’s oral and selective menin inhibitor, ziftomenib, on a conference call to be held on December 9 at 8 am. Webcast Link
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology management to meet with Cantor Fitzgerald
- BofA lowers Kura Oncology price target to $29, sees buying opportunity
- Nvidia reports Q3 beat, Starbucks explores China partnerships: Morning Buzz
- Kura Oncology price target lowered to $18 from $22 at Scotiabank
- Kura Oncology price target lowered to $34 from $37 at Wedbush